Provet Cloud vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Cloud Veterinary Information Management System
Cloud-based veterinary information management system acquired by Nordhealth; Helsinki Finland; serves 3,000+ clinics across Europe, Australia, New Zealand, and North America;
About
Provet Cloud is a cloud-based veterinary information management system (VIMS) that provides veterinary practices with patient records, appointment scheduling, invoicing, pharmacy management, lab integration, and reporting in a browser-accessible platform, developed and headquartered in Helsinki, Finland and acquired by Nordhealth, the Nordic health technology group. Provet Cloud serves more than 3,000 veterinary clinics across Europe, Australia, New Zealand, and North America, making it one of the most internationally deployed cloud-native veterinary practice management platforms available.\n\nProvet Cloud's platform is designed for general veterinary practices, emergency clinics, and specialty hospitals, offering a clinical workflow that tracks patients from check-in through consultation, diagnostics, treatment, and discharge with integrated invoicing and payment collection. Lab integrations connect directly to in-house analyzers and external diagnostic labs, bringing results into the patient record automatically. The platform's multi-location and multi-user architecture supports corporate veterinary groups and franchise networks that need consolidated reporting across clinics while maintaining individual clinic workflows. APIs allow integration with third-party diagnostic, imaging, and practice growth tools.\n\nAs part of Nordhealth, Provet Cloud benefits from investment in development resources and synergies with Nordhealth's other healthcare technology platforms. Provet Cloud competes with ezyVet (owned by IDEXX), Digitail, Vetspire, and the legacy PIMS offerings from IDEXX and Henry Schein. Its strong presence in European and Australasian markets differentiates it from US-centric competitors, and its API-first architecture appeals to technology-forward practices and corporate groups building integrated technology stacks.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.